News

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Leerink sees a $2.2 billion peptide market, with Hims potentially capturing about 20%.

An FDA advisory panel on Thursday recommended adding the peptide BPC-157 to a list that would allow compounding pharmacies to prepare it more freely for patients.

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.

One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...

Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. Hims & Hers rallied by 12.49 percent on Monday to finish at $30.17 apiece, as investors cheered rosy growth prospects for the obesity market, alongside its efforts to bridge the gap between the rapidly increasing demand […]

Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen. In this article, we will summarize the bears’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $27.51 as of June 2nd. HIMS’s trailing and forward P/E were 57.14 and 58.82 […]

Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.

The Eucalyptus deal supports Hims' goals of $6.5 billion in revenue and $1.3 billion EBITDA by 2030.

Hims & Hers Stock Pops After Board Member Makes Surprise $1.2 Million Purchase

Director David Wells acquires 48,400 shares

BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp-up in GLP-1 growth.

The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.

The stock continues to be very volatile.

The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.45%. June E-mini S&P futures (ESM26 ) are down -0.74%, and June E-mini Nasdaq futures...

Trump’s China summit threatens the AI boom, Ford gets into the energy storage business, Hims & Hers posts a surprise loss, and more news to start your day.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.

Senseonics (SENS) delivered earnings and revenue surprises of -9.23% and +16.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $29.76 as of April 21st. HIMS’s trailing and forward […]

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

OMCL vs. HIMS: Which Stock Is the Better Value Option?